Radiation therapy of early vocal cord carcinoma stage T1N0 twenty-one years' experience at Isaac González Martínez Oncologic Hospital

Se llevó a cabo un análisis detallado retrospectivo de 72 pacientes con cáncer de cuerda vocal estádio T1N0M0 tratados en el Departamento de Radioterapia del Hospital Oncológico Isaac González Martínez en San Juan, Puerto Rico desde enero de 1960 hasta diciembre de 1980. La edad de la mayoría de los pacientes fluctuaba de 50 a 79 años y el 88% eran varones. Todos los pacientes tuvieron un periodo de seguimiento mínimo de cinco años. La sobrevida global a cinco años fue de un 86% . Trece pacientes tuvieron recidiva local del tumor de los cuales diez fueron rescatados mediante cirugía. El control local final fue de un 96% . El tiempo medio para recidiva fue de 25 meses. Se diagnosticaron segundos tumores primarios en 12 pacientes durante el seguimiento. Los resultados de este estudio confirman el valor de la radioterapia como modalidad de tratamiento primário para el cáncer temprano de las cuerdas vocales ofreciendo una excelente curabilidad y preservación de la voz

The Management of Testicular Seminomas, 1979.

The reported results from throughout the world of modern treatment of testicular seminoma are reviewed for the various clinical stages of disease. The three-year survival rate for 1,346 patients with Stage 1 and 2 disease is 91%. Since the review reveals considerable differences in staging methods, a clinically useful staging system is proposed. Treatment methods are described and discussed. Recommendations are made assuming that patients so treated are clinically evaluated for extent of disease before treatment with currently available techniques, including lymphangiography, CT scanning, perhaps ultrasonography, and serum marker determinations. Although the role of cytoreductive surgery in patients with seminoma, even bulky seminoma, now is limited, occasionally when laparotomy is done, debulking may also be helpful. Effective combination chemotherapy regimens have not been identified. The 28% three-year survival rate of patients with Stage 3 disease establishes the real need to identify such therapy. Finally, anaplastic seminoma is considered; a recent review by Percarpio indicates that this subtype perhaps is not unlike classical seminoma as far as stage distribution and prognosis is concerned.